Los Angeles Capital Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Los Angeles Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	BUY	$76.68 - $93.31 $283,792 - $345,340	3,701 New	3,701 $337,000
Q3 2022 Nov 02, 2022	BUY	$44.76 - $69.66 $193,094 - $300,513	4,314 New	4,314 $295,000
Q2 2021 Aug 05, 2021	SELL	$40.9 - $64.9 $556,689 - $883,353	-13,611 Closed	0 $0
Q1 2021 May 05, 2021	BUY	$40.8 - $57.39 $196,084 - $275,816	4,806 Added 54.58%	13,611 $584,000
Q4 2020 Feb 04, 2021	BUY	$30.79 - $57.2 $11,238 - $20,878	365 Added 4.32%	8,805 $504,000
Q3 2020 Nov 02, 2020	BUY	$25.89 - $33.65 $218,511 - $284,006	8,440 New	8,440 $255,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.